CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy

• DOI: 10.1172/jci.insight.149819
• Publication Date: 2021-08-23T20:37:37Z
• Authors: Miriam Y. Kim; Matthew L. Cooper; Miriam T. Jacobs; Julie K. Ritchey; Julia Hollaway; Todd A. Fehniger; John F. DiPersio
• Keywords: Hematopoietic stem cell

Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor cells (UCART7) can lead to profound immune deficiency due loss of normal and NK cells. While a small population endogenous CD7- exists, these are unlikely be able repopulate the entire repertoire after UCART7 treatment, as they limited in number proliferative capacity. To rescue UCART7, we created hematopoietic stem genetically deleted for CD7 (CD7-KO HSCs). CD7-KO HSCs were engraft immunodeficient mice differentiate into lacking expression. could perform effector functions robustly control Furthermore, phenotypically functionally distinct from cells, indicating that supplement Mice engrafted maintained numbers while significantly decreased mice. These studies support development augment host immunity patients treatment.